Found 15 results
Author Title [ Type(Asc)] Year
Filters: Author is Boron, M  [Clear All Filters]
Journal Article
I. Hand, Boron, M., and Van Veldhuisen, P., Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry, 2001.
J. Romero, Cohen, A., Boron, M., and Rankin, M., RSV Prophylaxis in Minority Populations; Results from the Palivizumab Outcomes Registry 2002-2003, Pediatric Research, vol. 55, p. 237A, 2004.
A. Gelfand, Cohen, A., Boron, M., Rankin, M., and Group, theSynagis Ou, RSV prophylaxis in African American children; results from the Palivizumab outcomes registry, 2004.
A. Gelfand, Cohen, A., Boron, M., Rankin, M., and Group, theSynagis Ou, RSV prophylaxis in African American children; results from the Palivizumab outcomes registry, 2004.
A. Gelfand, Cohen, A., Boron, M., Rankin, M., and Group, theSynagis Ou, RSV prophylaxis in African American children; results from the Palivizumab outcomes registry, Am J Resp Crit Care Med, vol. 169, 2004.
A. Gelfand, Cohen, A., Boron, M., Rankin, M., and Group, T. Synagis®, RSV prophylaxis in 60 children with cystic fibrosis; results from the “Real World” experience - Palivizumab Outcomes Registry, 2004.
M. Speer, Cohen, A., Boron, M., Rankin, M., and Group, theSynagis Ou, Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease, 2004.
M. Speer, Cohen, A., Boron, M., Rankin, M., and Group, theSynagis Ou, Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting, Pediatric Research, vol. 55, p. 237A-238A, 2004.
M. Speer, Cohen, A., Boron, M., Rankin, M., and Group, theSynagis Ou, Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease, 2004.
M. Frogel, Nerwen, C., Boron, M., Cohen, A., Van Veldhuisen, P., and Harrington, M., Prevention of Hospitalization Due to Respiratory Syncytial Virus: Results from the Palivizumab Outcomes Registry, J Perinatol, vol. 28, pp. 511-517, 2008.
H. X. Chen, Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., and Kaplan, R. S., Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients with Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301, J Clin Oncol, vol. 24, pp. 3354-3360, 2006.
S. Cohen, Boron, M., Cohen, A., Van Veldhuisen, P., and Group, thePalivizuma, Patterns of RSV Disease Prophylaxis in Infants with Congenital Heart Disease (CHD): Preliminary Results From the 2002-2003 Palivizumab Outcomes Registry, J Perinatology, vol. 23, p. 594, 2003.
M. Hudak, Boron, M., Cohen, A., and Van Veldhuisen, P., Palivizumab prophylaxis of RSV disease: demographic and risk factors results from the 2002-2003 Outcomes Registry, J Perinatology, vol. 23, p. 592, 2003.
M. Frogel, Nerwen, C., Boron, M., Cohen, A., Van Veldhuisen, P., and Harrington, M., Improved Outcomes with Home-Based Administration of Palivizumab: Results from the 2000-2004 Palivizumab Outcomes Registry, J Perinatol, vol. 28, pp. 511-517, 2008.
S. Cohen, Boron, M., Cohen, A., Van Veldhuisen, P., and Registry, T. Palivizuma, Group patterns of RSV disease prophylaxis in infants with congenital heart disease (CHD): preliminary results from the 2002-2003 Palivizumab Outcomes Registry, 2003.